jRCT1031250782RecruitingNot Applicable
A prospective randomized controlled trial of remimazolam versus propofol on cerebral oxygenation during laminectomy in prone position under general anesthesia (PRO-REM Trial)
Not provided0 sites60 target enrollmentStarted: TBD
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
Eligibility Criteria
- Ages
- 65age old over to No limit (—)
- Sex
- All
Inclusion Criteria
- •Elderly patients over 65 years of age
- •Diagnosis: Patients with spinal disease at the thoracic and/or lumbar level requiring laminectomy, discectomy, and/or posterior spinal fusion
- •ASA classification: Patients classified as ASA I-III (including relatively healthy patients to patients with mild to moderate systemic disease)
- •BMI greater than or equal to 18 or less than or equal to 35
- •Able to tolerate prone position
- •Able to fully understand the study plan and provide informed consent on their own
- •Operating table: Spine surgery using a prone pillow, such as the Mizuno OSI Trios operating table or the Mizuno MOT-8300
Exclusion Criteria
- •Uncontrolled cardiovascular disease (e.g., EF<30% heart failure, Af, other severe arrhythmias)
- •Severe respiratory disease (e.g., chronic obstructive pulmonary disease, high-risk obstructive sleep apnea (vital capacity <60%, volume <50%))
- •Severe hepatic impairment (e.g., Child-Pugh classification C)
- •Severe neurological disease (assessed by mini-cog test)
- •History of allergy to remimazolam, propofol, benzodiazepines, or soy/egg-based products
- •Angle-closure glaucoma
- •Emergency surgery
- •Spine surgery requiring head fixation with 3-point fixation
- •Refusal to participate in the study
Investigators
Similar Trials
Completed
Phase 1
A trial to learn if different doses of REGN17092 are safe in healthy adults2023-505041-52-00Regeneron Pharmaceuticals Inc.128
Recruiting
Phase 1
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT2024-519010-31-00Fondazione Melanoma Onlus80
Not yet recruiting
Phase 4
Study of efficacy and side effects of imeglimin as an antidiabetic agent as single drug or as an add on drugCTRI/2024/04/065835Abhinav Garg200
Recruiting
Phase 2
Romiplostim in Inherited marrow failure syndromes - Safety and EfficacyCTRI/2024/03/063966INDIAN COUNCIL OF MEDICAL RESEARCH10
Recruiting
Phase 1
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96
